Evidence map›Paper›PMID 35332375›Full record

ArticleAnnals of hematology2022

Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation.

Lijie Han, Haiyan Zhang, Ping Ma, Jie Peng, Yilu Li, Jiaying Wu, Yuanyuan Li, Jifeng Yu, Wei Li, Mengmeng Zhang and 8 more

Abstract read
In one paragraph

Article in Annals of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Fecal Transplantation in Hematopoietic Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lijie Han *Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. hanlijiede@126.com.
Haiyan Zhang *Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ping Ma *Hematology/Oncology Department, Children's Hospital Affiliated To Zhengzhou University, Zhengzhou, China.
Jie PengDepartment of Oncology, the Second Affiliated Hospital of Guizhou Medical University, Kaili, China.
Yilu LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiaying WuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yuanyuan LiSchool of Foreign Languages, Henan University of Chinese Medicine, Zhengzhou, China.
Jifeng YuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wei LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Mengmeng ZhangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jia Bao HeDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhiping FanDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Weimin WangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Li'na SangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Hui SunDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qifa LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. liuqifa628@163.com.
Yang LiuDepartment of Radiotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. sunny5799@126.com.
Zhongxing JiangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. jiangzx@zzu.edu.cn.

Funding

Jointly Sponsored Project of Henan Medical Science and Technology Research Plan LHGJ20190040Key scientific research projects of colleges and universities in Henan Province 20B320048Medical Science and Technology Project of Henan Province SB201901106)National Key Research and Development Projects 2017YFA0105500
6 · The paper itself

Abstract

Intestinal microbiota is an important prognostic factor for allogeneic hematopoietic stem cell transplantation (allo-HSCT), but its role in predicting survival has not been determined. Here, stool samples at day 15 ± 1 posttransplant were obtained from 209 patients at two centers. Microbiota was examined using 16S rRNA sequencing. The microbiota diversity and abundance of specific bacteria (including Lachnospiraceae, Ruminococcaceae, Erysipelotrichaceae, and Enterobacteriaceae) were assigned a value of 0 or 1 depending on whether they were positive or negative associated with survival, respectively. An accumulated intestinal microbiota (AIM) score was generated, and patients were divided into low- and high-score groups. A low score was associated with a better 3-year cumulative overall survival (OS) as well as lower mortality than a high score (88.5 vs. 43.9% and 7.1 vs. 35.8%, respectively; both P < 0.001). In multivariate analysis, a high score was found to be an independent risk factor for OS and transplant-related mortality (hazard ratio = 5.68 and 3.92, respectively; P < 0.001 and 0.003, respectively). Furthermore, the AIM score could serve as a predictor for survival (area under receiver operating characteristic curve = 0.836, P < 0.001). Therefore, the intestinal microbiota score at neutrophil recovery could predict survival following allo-HSCT.

Indexed as

Gastrointestinal MicrobiomeGraft vs Host DiseaseHematopoietic Stem Cell TransplantationMicrobiotaBacillotaHumansRNA, Ribosomal, 16SRNA, Ribosomal, 16SAllogeneicHematopoietic stem cell transplantationIntestinal microbiotaSurvival

Identifiers

PMID35332375
PMCPMC9072276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.